Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet, show that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination. … [Read more...]
GlaxoSmithKline Applies for Approval of RTS,S Malaria Vaccine
A “pretty good” malaria vaccine is on track to be the first to market. It only prevents infection about one-quarter to one-half the time, so it’s not as good as most vaccines. But for a disease like malaria, which kills 600,000 people a year, “pretty good” may be good enough. GlaxoSmithKline has applied for regulatory approval for its RTS,S vaccine. Partial protection A new 18-month study in … [Read more...]
GlaxoSmithKline Seeks to Market RTS,S Malaria Vaccine
British drugmaker GlaxoSmithKline is seeking approval to market the world's first malaria vaccine, after trials showed that it significantly cut cases of the disease in children. Results from latest clinical trial of the RTS,S vaccine were unveiled at a conference in Durban, South Africa on Tuesday. It showed that after 18 months of follow-up, the vaccine halved the number of malaria cases … [Read more...]
Phase III Trial of RTS,S Malaria Candidate Vaccine Reduces Malaria by One Third
Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria. When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria … [Read more...]
GlaxoSmithKline Malaria Vaccine Candidate Results Disappointing
The latest clinical trial of the world’s leading malaria vaccine candidate produced disappointing results on Friday. The infants it was given to had only about a third fewer infections than a control group. Three shots of the vaccine, known as RTS, S or Mosquirix and produced by GlaxoSmithKline, gave babies fewer than 12 weeks old 31 percent protection against detectable malaria and 37 percent … [Read more...]
Malaria Vaccine
QUESTION Is there a vaccine for malaria? ANSWER No, as of yet there is not a vaccine available for malaria. The most promising vaccine candidate, RTS,S, which has been developed by GlaxoSmithKline, is currently undergoing Phase III trials in Africa. The trial is not due to finish until 2014, so we will have to wait until then to know how effective it is. Preliminary results, published … [Read more...]
Malaria Vaccine
QUESTION What is the shot you get to prevent malaria? ANSWER There is currently no shot available to prevent malaria. The most promising vaccine candidate, called RTS,S and being developed by GlaxoSmithKline, is currently undergoing Phase III trials in children in Africa. Preliminary results have indicated it may prevent up to 50% of malaria cases, though this varies by age group and … [Read more...]
Vaccine for Malaria
QUESTION Is there a vaccine to prevent malaria? ANSWER No, there is not currently a vaccine available to prevent malaria. The best current candidate, the RTS,S vaccine which was developed by GlaxoSmithKline, is currently undergoing Phase III clinical trials in Africa. Although preliminary results showed up to a 50% rate of protection against malaria in some age groups, the trials will not … [Read more...]
Why not create a vaccine for malaria?
QUESTION Why not create a vaccine for malaria? ANSWER There are many teams of scientists working hard to try to produce a malaria vaccine. In fact, only last year, the preliminary results of a vaccine trial were published. The vaccine, called RTS,S, has been produced by GlaxoSmithKline and is in the midst of Phase III trials in Africa. The preliminary results showed approximately a … [Read more...]
Malaria Vaccine Research
QUESTION Is there any research to produce anti malaria vaccine, if not, why? ANSWER There are many teams of scientists working hard to try to produce a malaria vaccine. In fact, only last year, the preliminary results of a vaccine trial were published. The vaccine, called RTS,S, has been produced by GlaxoSmithKline and is in the midst of Phase III trials in Africa. The preliminary … [Read more...]